QPPV.COM KNOWLEDGE ASSESSMENT

Efanesoctocog alfa: Discovery, Development, Safety and Pharmacovigilance โ€” Knowledge Assessment

Test your understanding of the concepts covered by Efanesoctocog alfa: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A team argues that efanesoctocog alfa is a gene therapy because it provides sustained FVIII activity. Which interpretation is most accurate?
Question 2 of 10 What is the most defensible interpretation of the absence of FVIII inhibitors in XTEND-1 and XTEND-Kids?
Question 3 of 10 A patient has breakthrough bleeding and a surprisingly high reported FVIII activity. The laboratory uses an assay known to overestimate efanesoctocog alfa activity. What is the most appropriate response?
Question 4 of 10 Why is batch and product traceability particularly important in a suspected biologic adverse reaction?
Question 5 of 10 How should FDA fast-track and breakthrough-therapy designations be interpreted?
Question 6 of 10 What is the most appropriate interpretation of a low ABR reported in a clinical trial?
Question 7 of 10 Why should the US and EU inhibitor frequency categories not be interpreted as directly measured efanesoctocog alfa trial incidence?
Question 8 of 10 A safety reviewer is assessing whether a reaction is listed for a suspected adverse reaction report. What is the best first step?
Question 9 of 10 Which set of information is most useful when investigating unexpected loss of efficacy?
Question 10 of 10 Which description best characterises the main XTEND-1 efficacy evidence?

Select an answer to continue.

QPPV.com